You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The acquisition will bring Technopath's chemistry and immunoassay controls into LGC's clinical diagnostics business unit.
The kit measures day-to-day test performance and has two configurations, one for IgG-specific tests and one for total antibody tests.
Native Antigen Company supplies native and recombinant infectious disease antigens, pathogen receptors, virus-like particles, and antibodies for immunoassays.
The kits have been validated at the US Centers for Disease Control and Prevention and the firm says 625 kits are now ready to ship.
The firms are also partnering to develop molecular diagnostic assays and for the supply of enzymes and oligonucleotides required for manufacturing.
LGC said the acquisition will improve its position across the clinical quality control tools market and increase its proficiency testing offerings.